<DOC>
	<DOCNO>NCT00004901</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one chemotherapy drug radiation therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy plus radiation therapy treat patient advanced mouth cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Advanced Mouth Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess feasibility administration ethynyluracil concurrently fluorouracil radiotherapy patient advanced oral cancer . II . Determine maximum tolerate dose ( MTD ) dose-limiting toxicity regimen patient population . OUTLINE : This dose escalation study fluorouracil hydroxyurea . Patients receive oral ethynyluracil every 12 hour day 1-7 oral fluorouracil every 12 hour day 2-6 . Radiotherapy head neck administer twice daily day 2-6 . Treatment continue 5-7 course absence unacceptable toxicity . Cohorts 3-6 patient receive escalate dos fluorouracil maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose limit toxicity . Once MTD fluorouracil determine , hydroxyurea add treatment regimen . Patients receive fluorouracil ethynyluracil per treatment schedule outline . Patients also receive oral hydroxyurea every 12 hour 11 dos day 1-6 . Radiotherapy administer . Cohorts 3-6 patient receive escalate dos hydroxyurea MTD determine . Once MTD fluorouracil hydroxyurea determine , additional 10 patient receive Phase II dose ethynyluracil , fluorouracil hydroxyurea per treatment schedule outline . Treatment continue absence unacceptable toxicity . Patients follow 4-6 week , every 6 month death . PROJECTED ACCRUAL : Approximately 40 patient accrue study 2 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Eniluracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced malignant oral laryngeal neoplasm require regional radiotherapy amenable standard therapy Tumor site amenable radiotherapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Expected 2 year survival le 10 % previously untreated patient Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hepatic : Not specify Renal : Creatinine clearance least 50 mL/min Other : No severe infection medical illness would preclude study Must able swallow retain oral medication Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Recovered prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Recovered prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2000</verification_date>
	<keyword>stage IV hypopharyngeal cancer</keyword>
	<keyword>recurrent hypopharyngeal cancer</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
</DOC>